Ethos Technologies Inc. Class A Common Stock
$ 16.34
1.43%
23 Apr - close price
- Market Cap 1,012,830,000 USD
- Current Price $ 16.34
- High / Low $ 16.53 / 16.11
- Stock P/E 14.13
- Book Value -1.45
- EPS 1.14
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.21 %
- 52 Week High 19.00
- 52 Week Low 9.45
About
aTyr Pharma, Inc., a clinical-stage biotherapeutics company, is dedicated to the discovery and development of drugs based on new immune pathways in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$20.25
Quarterly Earnings
| Dec 2025 | Sep 2025 | Mar 2024 | Dec 2023 | Sep 2023 | Dec 2022 | Jun 2022 | Mar 2022 | Sep 2021 | Mar 2021 | Sep 2020 | Mar 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-12-03 | 2024-05-29 | 2024-03-15 | 2023-10-03 | 2023-03-03 | 2022-07-21 | 2022-04-12 | 2021-10-12 | 2021-05-14 | 2020-10-30 | 2020-06-26 |
| Reported EPS | 0.42 | 0.27 | -0.23 | -0.23 | -0.2 | -0.26 | -0.44 | -0.44 | -0.42 | -0.64 | -0.68 | -0.69 |
| Estimated EPS | 0.4011 | 0 | -0.24 | -0.25 | -0.22 | -0.48 | -0.38 | -0.33 | -0.57 | -0.49 | -0.74 | -0.73 |
| Surprise | 0.0189 | 0.27 | 0.01 | 0.02 | 0.02 | 0.22 | -0.06 | -0.11 | 0.15 | -0.15 | 0.06 | 0.04 |
| Surprise Percentage | 4.712% | None% | 4.1667% | 8% | 9.0909% | 45.8333% | -15.7895% | -33.3333% | 26.3158% | -30.6122% | 8.1081% | 5.4795% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -2.43 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LIFE
2026-04-16 21:38:44
This article compiles several trade ideas and analyses for Ethos Technologies Inc. Class A (BX:LIFE, NASDAQ:LIFE). A key analysis suggests a long position around the $15 support level, with price targets at $16.90 and $17.88, due to stabilizing price action and optimistic social sentiment. Another detailed analysis focuses on aTyr Pharma (NASDAQ:LIFE)'s efzofitimod, highlighting its potential to monopolize the autoimmune market if its phase 3 trials for pulmonary sarcoidosis are successful.
2026-04-12 19:38:42
This page from TradingView displays the "Return on invested capital %" for Ethos Technologies Inc. Class A, traded on the BX Swiss exchange under the ticker LIFE. The content confirms the company and stock identifier while providing navigation to financial data and other related sections of the platform.
2026-04-12 17:10:13
This article focuses on the price-to-earnings (P/E) ratio of Ethos Technologies Inc. Class A (BX:LIFE). It highlights the company's financial overview, specifically its P/E ratio, within the context of the Technology Services and Packaged Software sectors on the BX Swiss exchange. The content primarily serves as a financial data point for investors researching Ethos Technologies.
2026-04-12 15:09:05
This article lists ETFs that hold Ethos Technologies Inc. Class A stocks, focusing on the Harbor Active Small Cap Growth ETF (SGRW) as a specific example. It provides financial data such as market value, weight, issuer, expense ratio, AUM, price, and performance for SGRW. The content highlights how ETFs can make stock investing more accessible and less risky.
2026-04-12 14:09:05
This article details the revenue breakdown for Ethos Technologies Inc. Class A (BX:LIFE). In the last fiscal year, the company generated 307.28 million CHF from its Life Insurance Services segment, with the United States being the primary geographical contributor. This represents an increase from 231.52 million CHF in the previous year.
2026-04-12 12:09:05
This article from TradingView provides an overview of Ethos Technologies Inc. Class A (BX:LIFE) financial statements. It includes details about the company's valuation, growth, profitability, and dividend policy, noting that LIFE has never paid dividends. The company provides life insurance services for debt, income, mortgages, and education, and was founded in 2016.
